Habib S. Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping. World J Gastrointest Pathophysiol 2024; 15(2): 92791 [PMID: 38845820 DOI: 10.4291/wjgp.v15.i2.92791]
Corresponding Author of This Article
Shahid Habib, MD, Doctor, Researcher, Department of Hepatology, Liver Institute PLLC, 3232 E Speedway Bvd, Tucson, AZ 85716, United States. shabib@liverinstitutepllc.org
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. May 24, 2024; 15(2): 92791 Published online May 24, 2024. doi: 10.4291/wjgp.v15.i2.92791
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
Shahid Habib
Shahid Habib, Department of Hepatology, Liver Institute PLLC, Tucson, AZ 85716, United States
Author contributions: Habib S hypothesis genesis, data collection, critical data review and synthesis, manuscript writing and submission.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shahid Habib, MD, Doctor, Researcher, Department of Hepatology, Liver Institute PLLC, 3232 E Speedway Bvd, Tucson, AZ 85716, United States. shabib@liverinstitutepllc.org
Received: February 5, 2024 Revised: April 4, 2024 Accepted: April 24, 2024 Published online: May 24, 2024 Processing time: 107 Days and 14.4 Hours
Core Tip
Core Tip: Metabolic dysfunctions-associated steatotic liver disease (MASLD) is a pathogenically heterogeneous disease with dynamic pathological features. The cardiometabolic risk of MASLD varies based on underlying etiopathogenic processes. Four subtypes of MASLD have been identified: Diabetic, non-diabetic (insulin resistance), genetic and mixed. These subtypes have not been clearly defined yet as separate entities. Given such heterogeneity, the behavior and outcome of MASLD in each patient is expected to be different. Therefore, a single drug is not expected to work for all patients with MASLD. The natural history of MASLD subtypes is unknown. There is an unmet need to categorize its subtypes and prospective studies are needed to characterize each subtype.
